Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial
Open Access
Abstract
This randomized, double-blind, placebo-controlled phase 1/2 trial aimed at evaluating the safety and immunogenicity of Ad5-nCoV via aerosolized or intramuscular or intramuscular–aerosolized routes in SARS-CoV-2-negative adults aged over 18 years. In the phase 1 trial, participants were sequentially enrolled into one of five regimen cohorts: Low-Dose (two doses of aerosolized Ad5-nCoV with 0.5 × 1010 viral particles [vps] per dose), Middle-Dose (two doses of aerosolized Ad5-nCoV with 1.0 × 1010 vps per dose), High-Dose (two doses of aerosolized Ad5-nCoV with 2.0 × 1010 vps per dose), Mixed (intramuscular Ad5-nCoV with 5.0 × 1010 vps [first dose] and aerosolized Ad5-nCoV with 2.0 × 1010 vps [second dose]), and Single-Dose (one dose of aerosolized Ad5-nCoV with 1.0 × 1010 vps). Eligible participants in the phase 2 trial were stratified by 18–59 years old or ≥60 years old and then were sequentially enrolled into one of six regimen cohorts: Low-Dose, Middle-Dose, High-Dose, Mixed, Single-Dose, and Intramuscular (one dose of intramuscular Ad5-nCoV with 1.0 × 1010 vps). The intervals between the two doses were 56 days. Participants were randomly allocated in 3:1 (phase 1) and 5:1 (phase 2) ratios to receive either Ad5-nCoV or the placebo in each cohort. This study is registered on ClinicalTrials.gov, NCT04840992. Most adverse reactions that occurred during the solicited period were mild and moderate. One serious adverse event (myelodysplastic syndrome) was considered potentially related to the aerosolized Ad5-nCoV. The GMTs of neutralizing antibodies in the Mixed group were the highest with 57.03 (95% CI: 23.95, 135.80) and 97.37 (95% CI: 74.30, 127.59) in phase 1 and 2 trials, respectively, 28 days after the second dose (p < 0.0001), which showed significantly higher immune responses compared to other regimens with aerosolized or intramuscular Ad5-nCoV alone.Keywords
Funding Information
- National Key R&D Program of China (2023YFC2307600, 82341031, 82173584, 82222062, 92269205, BK20220064, BE2021738, BE2023601)
- National Natural Science Foundation of China (2023YFC2307600, 82341031, 82173584, 82222062, 92269205, BK20220064, BE2021738, BE2023601)
- Major Research Plan of the National Natural Science Foundation of China (2023YFC2307600, 82341031, 82173584, 82222062, 92269205, BK20220064, BE2021738, BE2023601)
- Jiangsu Provincial Science Fund for Distinguished Young Scholars (2023YFC2307600, 82341031, 82173584, 82222062, 92269205, BK20220064, BE2021738, BE2023601)
- Jiangsu Provincial Key Project of Science and Technology Plan (2023YFC2307600, 82341031, 82173584, 82222062, 92269205, BK20220064, BE2021738, BE2023601)
This publication has 12 references indexed in Scilit:
- Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adultsNature Communications, 2023
- Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop reportnpj Vaccines, 2023
- Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialThe Lancet Respiratory Medicine, 2023
- Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory virusesCell Host & Microbe, 2023
- Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialThe Lancet, 2021
- Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trialThe Lancet Infectious Diseases, 2021
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic ThrombocytopeniaNew England Journal of Medicine, 2021
- Injection fears and COVID-19 vaccine hesitancyPsychological Medicine, 2020
- TH2 cell development and functionNature Reviews Immunology, 2017
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003